Two hours. That’s how long it will take from opening a website to getting a prescription for GLP-1 in your mailbox in 2026. A questionnaire (asking for your height and weight, no fact-checking), remote verification and validation by a clinician you’ll never meet.
A prescription means that a doctor has looked at you, assessed your condition and determined that medical intervention is necessary.
But the woman who filled out the short questionnaire on her phone is not sick. He just wants to get back into the jeans he hasn’t worn in two years. He did his research, he can do it drugand he spent years managing his body the hard way, calculating, restricting, training, and showing it off. That way, when the confirmation arrives in his inbox, he won’t feel like a patient. She feels like a woman who finally has access to something that actually works.
Do we leave it at that, or ask what it means that access to powerful prescription drugs now requires nothing more than a credit card and a Wi-Fi connection?
When semaglutide was first approved for weight managementyou needed a body mass index (BMI) of 30 or higher or a documented medical condition. The drug is intended for people whose severity is determined as a chronic disease. Then the thresholds disappeared. In March 2024, the Food and Drug Administration removed specific BMI requirements from the semaglutide label, in part to address the limitations of BMI as a measurement tool, which researchers have long noted was developed in European populations and does not translate well across organs. Seven months later, tirzepatide appeared.
Through the open door came the longing industry. Compounding pharmacies have produced cheaper off-brand versions, telehealth platforms built businesses around them, and suddenly ads were everywhere, aimed not at people who had struggled with obesity for decades, but at thin, young women who wanted to lose a few pounds before summer.
You know what you want. Do you know why?
The telehealth questionnaire will ask for your weight, which may be completely within the normal range. When you grow up, your mother won’t ask you what she said about her body.
This memoryfor many women, this is where the story really begins. And yet, the desire to lose weight among women who don’t need to lose weight is so normalized that it barely registers as a story. In 2025, 61 percent of American women say they want to lose weight, a number that has remained remarkably stable since 1951, regardless of what the culture tells women about body positivity.
The desire to be thin is personal, but research shows that it is largely borrowed. So when you think that conscious consent is a straightforward thing you read, understand, and decide, it’s worth stopping at the underlying assumption: the desire itself came about independently. And for body imageto feel that you are standing in front of a mirror, which is almost never true.
Women who internalize the cultural ideal of thinness tend to aspire to it because they associate being thinner with psychological rewards. trust and happinessand social ones like good relationships and professional success. And it runs deeper than aspiration. Research shows that being overweight is culturally associated with laziness and lack of discipline, associations that have nothing to do with health, and everything to do with moral judgment. Researchers have found that body dissatisfaction and the desire to lose weight are primarily related to the internalization of these cultural ideals, rather than an objective assessment of your body. A woman who orders GLP-1 online and does her research is still making decisions within her unwritten story.
His choice is valid, but so is the question of what is actually being treated. Because if a size 4 is good for a prescription, and the desire to downsize is statistically more driven by social norms than health, then what we’ve built is a very effective delivery mechanism for a very outdated one. worrythis time in drug form.
The price no one told you about
A confirmation email will arrive in your inbox. It does not include the conversation that this drug will cost you psychologically, not financially.
Research on mental health and GLP-1 is related to prescriptions that are still being written. A large cohort study conducted in 2024 found a significant association between GLP-1 treatment and the risk of major disease. depression and anxiety. The 2025 document says the drugs can cause depression commit suicide idea, especially in people with a genetic predisposition to low levels dopamine function. Other studies have found no psychiatric risk, and some have even shown reduced symptoms of depression. The science isn’t settled, and it’s rarely part of the conversation before you sign up.
Subtlety has never been free. You have always paid for it with some currency, limitation, obsession, time, self-criticism. GLP-1 questions whether you’ve simply found a more efficient payment method, or whether efficiency equates to safety.
Who decides that? You, ideally. However, if someone asked you the questions first, the application will not be left.
